Tyrosine kinase inhibitors (TKI) have revolutionized the treatment of patients with chronic
myeloid leukemia. Patients who achieve sustained deep molecular response are eligible for …

Background: Droplet digital polymerase chain reaction (ddPCR) is an exact method of
measurement. Objectives: We conducted this study to identify the prognostic factors for …

We analyzed BCR:: ABL1 expression at stop and in the first month after discontinuation in
168 chronic myeloid leukemia patients who stopped imatinib or 2nd generation tyrosine …

Background: The advent of tyrosine kinase inhibitors (TKI) has decisively improved the
survival of patients with chronic myeloid leukemia (CML). Many patients achieve deep …

Achieving major molecular response (MMR) with BCR:: ABL1 tyrosine kinase inhibitors
(TKIs) is associated with lower chances of progression to advanced phase disease and …

Opinion statement ABL1 tyrosine kinase inhibitors (TKI) have dramatically improved the
outcome for CML (chronic myeloid leukemia) patients. When TKI therapy is addressed …

The primary goal of tyrosine kinase inhibitor (TKI) therapy for patients with chronic myeloid
leukemia is survival, which is achieved by the vast majority of patients. The initial response …

BACKGROUND To the authors' knowledge, the optimal frequency of monitoring after
tyrosine kinase inhibitor (TKI) discontinuation in patients with chronic myeloid leukemia …

ABSTRACT Introduction: Tyrosine kinase inhibitors (TKIs), which target BCR-ABL1 kinase
activity, have significantly prolonged the overall survival of patients affected by chronic …

The availability and affordability of multiple BCR:: ABL1 tyrosine kinase inhibitors (TKIs)
beginning in 2000 have changed the prognosis and treatment dynamics in Philadelphia …